The opportunity: the upstream
recognition layer
A platform company, not a single asset
The problem
Many solid tumors evade immune recognition, limiting current immunotherapies.
The platform
Four programmable layers designed to make tumors recognizable.
The pipeline
Two initial indications, MSS CRC and PDAC, studied in parallel.
The IP
27 provisional patent applications across four IP domains.
Why LurexBio
Built for the step today’s immunotherapies depend on.
LurexBio is designed to work upstream of today’s immunotherapies, at the recognition step they depend on. Its modular architecture is intended to support multiple programs, partnerships, and licensing opportunities on one shared platform.
- 4
- Programmable platform layers
- 27
- Provisional patent applications
- 13+
- Inventive embodiments
- 2
- Initial indications in parallel
01 · The market
One of the largest, fastest-growing markets in healthcare.
$441Bprojected global spending on cancer medicines in 2029
$144B
$252B
$441B
Spending grew 75% in the five years to 2024. The 2019 value is implied by that growth rate.
| 2019 (implied) | $144B |
|---|---|
| 2024 | $252B |
| 2029 (forecast) | $441B |
02 · The gap
Immunotherapy has proven its value, but most patients still don’t benefit.
$31.7B2025 sales of a single checkpoint inhibitor, Keytruda
- 12.5%estimated to respond
- 31.2%eligible, but not expected to respond
- 56.4%not eligible
Share of US patients with cancer, checkpoint inhibitors, 2018. Each square is 1%.
Recognition engineering is designed to address one reason many tumors don’t respond: the immune system can’t see them.
Sources: Merck full-year 2025 results · Haslam & Prasad, JAMA Netw Open 2019
03 · Our starting point
Two of the hardest-to-treat cancers, with high unmet need.
108KUS deaths expected in 2026 from colorectal and pancreatic cancer combined
Colorectal cancer55,230
Pancreatic cancer52,740
Sources: American Cancer Society, 2026 · ACS Cancer Statistics 2026, via PanCAN · Clin Adv Hematol Oncol, 2022
04 · The timing
Large pharma needs what comes next.
$500B+in worldwide drug sales at risk from patent expiry, 2026 to 2032
- 2028Keytruda approaches patent expiry, with $99B in industry sales at risk that year alone
- 2031The largest single year of exposure, at $158B
LurexBio’s platform is designed to support multiple programs, partnerships, and licensing opportunities.
Request the investor packageMarket and disease figures are drawn from the published sources linked and are not LurexBio results. LurexBio is a preclinical-stage company; statements about potential are forward-looking and subject to risks and uncertainties.
Our founder
James Clark
Founder & Inventor · Stage IV cancer survivor
LurexBio was founded at the intersection of personal urgency and disciplined inquiry. During treatment for advanced cancer, James undertook an intensive, multi-year study of immunology and emerging therapeutic technologies, seeking to understand why the immune system fails to recognize many solid tumors.
That investigation led to a core insight: in many cancers, the limitation is not the strength of the immune response, but the absence of effective recognition. From that idea grew a structured platform architecture and the foundation of LurexBio’s approach.
“The search for answers began as one person’s fight for survival and became a mission to help others. Science gave me clarity, collaboration gave me direction, determination gave me purpose.”James Clark, Founder
- Stage IVcancer survivor
- Inventorof the LurexBio platform
- 27provisional patent applications
Led by an
experienced team and
world-class advisors.
Scientific Advisory Board
Deep experience across oncology, immunology, drug development, healthcare technology, and translational execution.
- Dusan Kostić, PhDChair
- Andrej Jedinak, PhDAdvisor
- Maëlig Morvan, PhDAdvisor
- Dr. Israel Wiznitzer, MDAdvisor
- Dr. Fred McCall-Perez, PhD/MBAExecutive Sponsor
LurexBio is a preclinical-stage company. Nothing on this site is an offer to sell, or a solicitation of an offer to buy, any securities.
Statements about plans and objectives are forward-looking and subject to risks and uncertainties.